Search

Your search keyword '"Jonathan H. Goldman"' showing total 5 results
Start Over Author "Jonathan H. Goldman" Journal international journal of radiation oncology*biology*physics
5 results on '"Jonathan H. Goldman"'

1. Impact of Prior Radiation Therapy on the Efficacy and Toxicity of Pembrolizumab in the Treatment of Non–small Cell Lung Cancer

Author

Narek Shaverdian, K. Bornazyan, A.E. Lisberg, Percy Lee, Jonathan H. Goldman, Darlene Veruttipong, Silvia C. Formenti, and Edward B. Garon

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, Pembrolizumab, medicine.disease, Internal medicine, Toxicity, medicine, Radiology, Nuclear Medicine and imaging, Non small cell, Lung cancer, business, Prior Radiation Therapy
Published
2017

2. Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

Author

Allen C. Chen, Scott J. Antonia, Hossein Borghaei, Yun Shen, Scott N. Gettinger, Rosalyn A. Juergens, Naiyer A. Rizvi, Neal Ready, Jonathan H. Goldman, Julie R. Brahmer, Laura Q.M. Chow, and Christopher T. Harbison

Subjects
Oncology, Cancer Research, medicine.medical_specialty, education.field_of_study, Radiation, business.industry, First line, Anti pd 1, Population, non-small cell lung cancer (NSCLC), Stock options, Ipilimumab, medicine.disease, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Nivolumab, education, business, medicine.drug
Abstract

an AESI reported in 2% of pts in the N single-agent treatment to progression phase were rash (Any Gr: 25.5%; Gr 3: 4.0%, hypomagnesemia (Any Gr: 16.0%; Gr 3: 2.5%), conjunctivitis (Any Gr: 4.7%; Gr 3: 0.7%), venous thromboembolic events (Any Gr: 2.5%; Gr 3 1.8%), and arterial thromboembolic events (Any Gr: 2.2%; Gr 3: 1.8%). Conclusions: OS and PFS were statistically significantly improved when N was added to GC. Pts who continued on N single-agent to progression had substantially better outcomes than the general population, and long-term use of N did not result in any unexpected increases in AESIs. Author Disclosure: M.A. Socinski: None. N. Thatcher: F. Honoraria; Eli Lilly and others. H. Speakers Bureau; Eli Lilly and others. K. Advisory Board; Eli Lilly and others. A.V. Luft: None. A. Szczesna: None. T. Ciuleanu: None. W. Szafra nski: None. R. Ramlau: None. B. Balint: None. A. Kazarnowicz: None. O. Molinier: G. Consultant; Eli Lilly. K. Advisory Board; Roche. H. Depenbrock: A. Employee; Eli Lilly. M. Stock; Eli Lilly. S. Nanda: A. Employee; Eli Lilly. M. Stock; Eli Lilly. C. Obasaju: A. Employee; Eli Lilly. M. Stock; Eli Lilly. N. Stock Options; Eli Lilly. L. Paz-Ares: F. Honoraria; Eli Lilly.

Published
2014

3. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Author

Scott A. Laurie, Laura Q.M. Chow, Allen C. Chen, Yun Shen, Frances A. Shepherd, Rosalyn A. Juergens, Hossein Borghaei, David E. Gerber, Christopher T. Harbison, Jonathan H. Goldman, Naiyer A. Rizvi, Scott J. Antonia, Scott N. Gettinger, and Julie R. Brahmer

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, Radiation, business.industry, medicine.medical_treatment, Anti pd 1, non-small cell lung cancer (NSCLC), chemistry.chemical_element, medicine.disease, chemistry, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Nivolumab, Platinum, business
Published
2014

4. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

Author

Allen C. Chen, Julie R. Brahmer, Christopher T. Harbison, Jonathan H. Goldman, Naiyer A. Rizvi, Neal Ready, David E. Gerber, Frances A. Shepherd, Scott J. Antonia, Hossein Borghaei, Laura Q.M. Chow, Yun Shen, Rosalyn A. Juergens, and Scott N. Gettinger

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Radiation, business.industry, First line, Anti pd 1, Cancer, non-small cell lung cancer (NSCLC), medicine.disease, Internal medicine, Cancer centre, medicine, Radiology, Nuclear Medicine and imaging, University medical, Non small cell, Nivolumab, business
Abstract

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status Metastatic Non-Small Cell Lung Cancer N.A. Rizvi, F.A. Shepherd, S.J. Antonia, J.R. Brahmer, L.Q. Chow, J. Goldman, R. Juergens, H. Borghaei, N.E. Ready, D.E. Gerber, Y. Shen, C. Harbison, A.C. Chen, and S. Gettinger; Memorial Sloan Kettering Cancer Center, New York, NY, Princess Margaret Cancer Centre, Toronto, ON, Canada, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, University of Washington, Seattle, WA, University of California, Los Angeles, Los Angeles, CA, Juravinski Cancer Centre at McMaster University, Hamilton, QC, Canada, Fox Chase Cancer Center, Philadelphia, PA, Duke University Medical Center, Durham, NC, UT Southwestern Medical Center, Dallas, TX, BristolMyers Squibb, Princeton, NJ, Yale Cancer Center, New Haven, CT

Published
2014

5. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy

Author

Yun Shen, Scott J. Antonia, Scott N. Gettinger, Frances A. Shepherd, Jonathan H. Goldman, Naiyer A. Rizvi, Allen C. Chen, and Laura Q.M. Chow

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, education.field_of_study, Radiation, Bevacizumab, business.industry, medicine.medical_treatment, Anti pd 1, Population, Stock options, non-small cell lung cancer (NSCLC), medicine.disease, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Nivolumab, Previously treated, education, business, medicine.drug
Abstract

an AESI reported in 2% of pts in the N single-agent treatment to progression phase were rash (Any Gr: 25.5%; Gr 3: 4.0%, hypomagnesemia (Any Gr: 16.0%; Gr 3: 2.5%), conjunctivitis (Any Gr: 4.7%; Gr 3: 0.7%), venous thromboembolic events (Any Gr: 2.5%; Gr 3 1.8%), and arterial thromboembolic events (Any Gr: 2.2%; Gr 3: 1.8%). Conclusions: OS and PFS were statistically significantly improved when N was added to GC. Pts who continued on N single-agent to progression had substantially better outcomes than the general population, and long-term use of N did not result in any unexpected increases in AESIs. Author Disclosure: M.A. Socinski: None. N. Thatcher: F. Honoraria; Eli Lilly and others. H. Speakers Bureau; Eli Lilly and others. K. Advisory Board; Eli Lilly and others. A.V. Luft: None. A. Szczesna: None. T. Ciuleanu: None. W. Szafra nski: None. R. Ramlau: None. B. Balint: None. A. Kazarnowicz: None. O. Molinier: G. Consultant; Eli Lilly. K. Advisory Board; Roche. H. Depenbrock: A. Employee; Eli Lilly. M. Stock; Eli Lilly. S. Nanda: A. Employee; Eli Lilly. M. Stock; Eli Lilly. C. Obasaju: A. Employee; Eli Lilly. M. Stock; Eli Lilly. N. Stock Options; Eli Lilly. L. Paz-Ares: F. Honoraria; Eli Lilly.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results